2/6/2024 0 Comments Download the new version Zoeti![]() ![]() ![]() Solensia aims to alleviate that pain and improve cats’ physical activity of levels and overall quality of life. Gruen, DVM, MVPH, PhD, DACVB, Assistant Professor of Behavioral Medicine at North Carolina State University. “OA pain can affect cats in various ways, often impairing their ability to perform daily activities such as jumping and playing, which negatively impacts their quality of life,” explains Margaret E. Undertreated OA pain can limit quality of life As monoclonal antibodies, they are eliminated by the body in the same way as naturally occurring proteins, with minimal involvement of the liver or the kidney 4. Librela (bedinvetmab) and Solensia (frunevetmab) work by targeting Nerve Growth Factors (NGF), which have key involvement in OA pain 2. Nerve Growth Factors: how do the drugs work in treating OA pain? With Solensia for cats and Librela for dogs, veterinarians will now have access to once-monthly breakthrough solutions for the management of pain associated with osteoarthritis – offering a new alternative to veterinarians to improve the quality of life for pets and their owners.” Mike McFarland, DVM, Executive Vice President and Chief Medical Officer at Zoetis, explains: “This can lead to under-treatment of OA pain. There are also issues with owner compliance and difficulty in administering NSAIDs in some patients. Some dogs and cats may have concurrent conditions that require administration of several medications, and some may not be able to tolerate NSAIDs as a result of other conditions. Although effective, administering NSAIDs comes with limitations. Globally, osteoarthritic pain impacts almost 40% of cats and dogs suffering from the condition 1,2, with NSAIDs being one of the most common treatment options 2. ![]() Advancements in treatment of osteoarthritis The new osteoarthritis products will be available to vets in the European union, United Kingdom and Switzerland in May. Zoetis has announced the launch of LIBRELA® (bedinvetmab) and SOLENSIA® (frunevetmab) in Europe, which are the first products in a new class of medications for the management of osteoarthritis (OA) pain in dogs and cats in 20 years. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |